Sign In
Free Newsletter
Princeton-based BioCentriq rebrands
Founded in 2019 as a New Jersey Innovation Institute subsidiary, a South Korean buyer bought the cell therapy contract development and manufacturing organization for $73 million in May 2022.
BioCentriq strikes deal for Princeton HQ, manufacturing facility (updated)
The new, long-term lease includes an immediate $12 million capital investment in facility upgrades, equipment and business system enhancements.
BioCentriq, Cytiva receive funding to accelerate gene therapy development
According to Emmanuel Abate, president, Genomic Medicine, Cytiva, “[C]ollaborations are essential to solve the challenges of bringing future therapeutics to market."
BioCentriq officially opens South Brunswick facility
CEO Haro Hartounian said the additional GMP manufacturing site is part of the company's expansion plan and allows it to "take on more projects to help biotech companies bring their products from bench to market, which is what we do best."
New Jersey Innovation Institute sells BioCentriq for $73M
Haro Hartounian – founder, senior vice president and general manager of the NJII subsidiary – will become CEO after the deal closes and retain his position as affiliated faculty at New Jersey Institute of Technology, which launched NJII in 2014 to serve as a platform for partnerships such as this.
South Korean company to acquire BioCentriq
GC Corp. said the Newark-based CDMO, which develops and manufactures cell and gene therapies, will maintain its individuality while sharing best practices with the new parent firm.
BioCentriq expands its clinical manufacturing facilities
The cell and gene-therapy process developer and clinical manufacturing center completed construction on a 9,000-square-foot facility.
